Integra LifeSciences Holdings Corp. (IART) Issues FY14 Earnings Guidance
Integra LifeSciences Holdings Corp. (NASDAQ:IART) updated its FY14 earnings guidance on Tuesday. The company provided EPS guidance of $3.00-3.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.13, AnalystRatings.NET reports. The company issued revenue guidance of $920-940 million, compared to the consensus revenue estimate of $925.28 million.
A number of research firms have recently commented on IART. Analysts at Barclays raised their price target on shares of Integra LifeSciences Holdings Corp. from $45.00 to $50.00 in a research note on Thursday, January 9th. They now have an equal weight rating on the stock. On a related note, analysts at Bank of America upgraded shares of Integra LifeSciences Holdings Corp. to a neutral rating in a research note on Wednesday, January 8th. Finally, analysts at Bank of America upgraded shares of Integra LifeSciences Holdings Corp. from an underperform rating to a neutral rating in a research note on Wednesday, January 8th. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $46.88.
Integra LifeSciences Holdings Corp. (NASDAQ:IART) opened at 47.41 on Tuesday. Integra LifeSciences Holdings Corp. has a 52 week low of $30.87 and a 52 week high of $49.90. The stock has a 50-day moving average of $47.25 and a 200-day moving average of $44.2. The company’s market cap is $1.333 billion.
Integra LifeSciences Holdings Corp. (NASDAQ:IART) last announced its earnings results on Tuesday, February 25th. The company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by $0.03. The company had revenue of $220.80 million for the quarter, compared to the consensus estimate of $223.37 million. On average, analysts predict that Integra LifeSciences Holdings Corp. will post $2.52 earnings per share for the current fiscal year.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.